Stutsman County Commission approves request for applications for vacant seat
The county commission is expected to make a decision on who will fill the vacant seat at its regular meeting on May 20.
The county commission will hold a special meeting, if needed, on May 20 before its regular meeting to go over the applications.
The deadline to apply for the vacant seat is noon May 16. The commissioner's term will commence immediately after the county commission's appointment.
The vacancy was created after the death of Commissioner Jerry Bergquist on April 24. He was elected to the commission in November 2022.
The appointee will hold the office at least until the next general election. North Dakota Century Code 44-02-05 says the appointee holds office until the appointee's successor is elected at the next general election that occurs at least 95 days after the vacancy and the successor has qualified. The next general election is in November 2026.
State's Attorney Fritz Fremgen said the last time an appointment was made to the Stutsman County Commission in September 2023 the four commissioners voted for an applicant. If someone received three or more votes, the individual was appointed to the county commission.
Fremgen said in the case of a 2-2 tie for two applicants, the county commission could call for another elected official to break the tie. Fremgen recommended Stutsman County Sheriff Chad Kaiser to be the elected official to break the tie since the state's attorney advises the county commission.
To apply for the vacant county commission seat, visit,
https://shorturl.at/xyA6V
.
The county commission unanimously approved purchasing a building that will be installed in Buchanan.
The county commission approved the purchase of property in Buchanan in October 2023 to construct a building to store its blade.
The total cost of the building and to install it is about $120,000, said Jesse Christianson. He said the post building is walk-in ready.
Christianson said it will cost over $13,000 to get electricity to the building and more than $17,000 for heating, which includes floor heat.
He said there will be additional expenses including electrical work to the interior and hooking up water.
Stutsman County will send a letter to Kidder County and Peterson and Williams townships about creating an access point for farmers west of Medina.
Stutsman County Road 39 west of Medina was closed due to high water making it unsafe and unpassable.
Christianson said County Road 39 will be closed until water can be drained from Stink Lake.
"As of right now, I just don't see that we can do anything with it," he said. "The way the water is coming up is deteriorating fast. It's not safe to travel."
An access road would be created at 35th Street Southeast that goes west to 47th Avenue Southeast. Christianson agreed with Commissioner Mike Hansen that it would be a minimum-maintenance road.
Christianson said the estimated cost to create the access road would be about $130,000. He said adding gravel to it would cost an additional $10,000 to $20,000.
"This is kind of roughing it in to get it as travelable as it could be," he said.
Christianson said the access road is owned by Kidder and Stutsman counties and Peterson and Williams townships.
No timeframe was given when work would start to create the access road.
Jessica Alonge, Stutsman County auditor/chief operating officer, said a formal letter should be sent to Kidder County and Peterson and Williams townships. She said county funds shouldn't be spent on the access road without having other legal pieces figured out.
Commissioner Levi Taylor said the letter should ask for a response from Kidder County and Peterson and Williams townships and ask them if they would be interested in a meeting. A meeting will be scheduled if there is interest for one.
Stutsman County Park Board will receive a $218,000 grant through the North Dakota Parks and Recreation Department's Recreational Trails Program.
The county's share is $36,000 for the 80-20 grant. The $36,000 can include in-kind donations, including labor.
With the grant funds, Stutsman County Park Board member Henry Steinberger said 25 concrete picnic tables can be purchased at $1,000 for each one. The grant funds can also be used for docks for less than $20,000 each and a Toolcat for under $100,000.
Steinberger said the park board has through June 2026 to complete the projects.
Alonge said the grant hasn't been accepted by the county yet and to not order anything until a contract for the grant is completed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Enlivex advances lead cell therapy to Phase IIb in osteoarthritis
Enlivex Therapeutics is planning to advance its lead cell therapy asset, Allocetra, to Phase IIb trials following the positive results from the primary group of its Phase I/IIa study in knee osteoarthritis (KOA). Though the resident macrophage-targeting therapy failed to have a statistically significant impact on the study's entire patient population, three biweekly doses of the drug were shown to statistically reduce Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores associated with knee pain, function and stiffness in a primary osteoarthritis (POA) population. During the ENX-CL-05-001 (NCT06233474) study, the POA group – which is categorised by disease onset due to ageing and general joint wear and tear – experienced a 72% reduction in WOMAC knee pain scores compared to placebo, while function scores increased by 95%. Both figures were statistically significant, with p values of 0.03 and 0.007, respectively. Allocetra also significantly improved WOMAC stiffness and function change, as well as pain and function change scores – boosting these by 47% and 49%, respectively. Following the positive results of the Phase I/IIa trial, Enlivex plans to obtain regulatory approval from the US Food and Drug Administration (FDA) for a Phase IIb trial of Allocetra, which the company estimates will come by Q2 of 2026. According to this timeline, the biopharma expects to dose the first patient in this trial by Q3 of 2026. These results come at a time when there is a strong unmet need for patients with KOA, as the non-surgical current treatment landscape revolves around the use of steroids and non-steroidal anti-inflammatory drugs (NSAIDs) like naproxen and ibuprofen. Though there are limited treatment options available for patients, the osteoarthritis market was worth $2.5 billion in 2021, according to a report by the parent company of Clinical Trials Arena, GlobalData. However, to be successful in this indication, Allocetra may have to fend off competition from other drug candidates moving forward, as there are currently 30 ongoing Phase III clinical trials assessing the efficacy of biologic drugs for osteoarthritis. This includes R-Biopharm's autologous stem cell therapy, JointStem, which was granted Breakthrough Therapy designation by the US Food and Drug Administration (FDA) in March 2025. "Enlivex advances lead cell therapy to Phase IIb in osteoarthritis" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
- In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee pain and 26% improvement in knee function, were observed in the AllocetraTM treatment arm vs placebo; moreover, 72% reduction in knee pain and 95% improvement in knee function were observed for age-related primary osteoarthritis patients compared with placebo – a substantial, clinically meaningful and statistically significant effect in commonly used Phase III primary endpoints for knee osteoarthritis clinical trials. - Favorable safety profile – No severe adverse events; limited, typically mild to moderate, transient, and treatable side effects occurred in most patients treated with Allocetra™ - Webinar today at 8:00 a.m. Eastern Time Nes-Ziona, Israel, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the 'Company'), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive three-month topline data from the Phase IIa stage of ENX-CL-05-001, a multi-center, two-stage Phase I/II double-blind, randomized, placebo-controlled clinical trial evaluating Allocetra™ in patients with moderate-to-severe knee osteoarthritis. Oren Hershkovitz, Ph.D, CEO of Enlivex, commented, 'We are excited to share the topline three-month data from ENX-CL-05-001. We believe these results provide clear indication that Allocetra™ has the potential to become a novel, safe and effective treatment for knee osteoarthritis, a growing market with significant unmet medical need.' The Company will host a webinar today at 8:00 am Eastern Time to provide in-depth analysis of the results. To join the webinar, please click To join the webinar, please register at: It is suggested participants join the webinar at least 15 minutes prior to the scheduled start time to avoid any delays in attendance. About ENX-CL-05-001ENX-CL-05-001 is a multi-center Phase I/II clinical trial consisting of two stages. The first stage was a Phase I safety run-in, open-label dose escalation phase to characterize the safety and tolerability of Allocetra™ injections to the target knee, in order to identify the dose and injection regimen for the subsequent Phase IIa stage. The Phase IIa stage is a double-blind, randomized, placebo-controlled multi-centered trial. In addition to evaluating safety, the study protocol was designed to efficiently find a strong signal in a responder population to guide future development, and includes an interim statistical evaluation, conducted by an independent third party and blinded to the Company, to assess the potential value of enrollment of up to 50 patients in addition to the original randomized sample size of 130, and its marginal impact on the p-value of the statistical estimation of the total group and specifically to identify a potential responder sub-group. The trial's key efficacy endpoints evaluate joint-pain and joint-function in comparison to placebo at three months, six months and 12 months post treatment. ABOUT KNEE OSTEOARTHRITIS Osteoarthritis is by far the most common form of arthritis, affecting more than 32.5 million Americans and more than 300 million individuals worldwide. About half of knees with ACL injuries develop osteoarthritis within 5 to 15 years. 78 million Americans are projected to have osteoarthritis by the year 2040. Symptomatic knee osteoarthritis is particularly prevalent and disabling, with 40% of men and 47% of women developing knee osteoarthritis in their lifetimes. Osteoarthritis accounts for over one million hospitalizations annually in the United States, primarily for total joint replacement. The burden of osteoarthritis is enormous, and the need for treatments that reduce pain and attendant disability for persons with osteoarthritis is critical. There are currently no medications approved by either the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) that have been demonstrated to arrest, slow or reverse progression of structural damage in the joint. ABOUT ENLIVEX Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life debilitating conditions. For more information, visit Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as 'expects,' 'plans,' 'projects,' 'will,' 'may,' 'anticipates,' 'believes,' 'should,' 'would,' 'could,' 'intends,' 'estimates,' 'suggests,' 'target,' 'has the potential to' and other words of similar meaning, including statements regarding expected cash balances, expected clinical trial results, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex's business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex's filings with the Securities and Exchange Commission, including in the Company's most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law. ENLIVEX CONTACT Shachar Shlosberger, CFOEnlivex Therapeutics, INVESTOR RELATIONS CONTACT Dave Gentry, CEORedChip Companies Inc.1-407-644-4256ENLV@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Tom's Guide
11-08-2025
- Tom's Guide
Terra Kaffe's new Demi machine is as small as a pod coffee maker, but brews proper espresso
Terra Kaffe is responsible for creating one of the best espresso machines we've ever reviewed, the TK-02. So, when we heard there's a new Terra Kaffee machine on the market, we knew we had to talk about it. But, what's so special about Terra Kaffe? Well, it's a super smart and futuristic coffee brand – two features that level up traditional coffee making and make us just a little bit excited. Not only is the TK-02 a high-end machine with intelligent technology, it's also incredibly slimline, taking up little space on your kitchen countertop. And all this has been implemented into its brand new machine, Demi – as small as a pod coffee maker, but brews proper espresso. It looks like something you'd find in a gentrified cafe or an art studio, I almost don't feel trendy enough to own it. But, I most certainly want one. Demi is Terra Kaffe's answer to stylish coffee and home espresso. Offering barista-level brewing without the waste, this new addition to the trendy coffee brand's range is sleek, mess-free and capable of a multitude of brews. And it's available to pre-order in four trendy colorways, each for $795. Demi is coined to be Terra Kaffe's "most compact, accessible, and aesthetically refined release to date". And, with an attractive minimalist interface that screams sleek and modern, I have to agree. It's not all about looks though (even if Demi is incredibly stylish), Terra Kaffe has crafted a fully zero-waste machine that uses no pods, plastic, or aluminum, without sacrificing on ability. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. And with it, there's a range of brewing options built in, which means you can make espresso, lungo, Americano and drip coffee all at the push of a button – adjusting strength, temperature and volume as you go. Terra Kaffe is also dedicated to seamless integration into your kitchen with a slimline build and compact footprint. For the Demi, it's just over 10" wide, which is comparison to the likes of Nespresso Vertuo Plus (9.7") or Keurig K-Supreme (8.3"), it's a competitive build. And then we have to take a look at the price. While $795 may seem expensive at first glance, it's worth weighing it up against the other bean to cup automatic coffee machines on the market. The De'Longhi Rivelia, for example, will cost you $1500. The Jura E8, a whopping $2699 or even their entry-level offering, the ENA 4, is $1199. So, when you put it into perspective, it's actually incredibly reasonable, especially when you compare the huge range of drink options available in the Demi. Plus, it's also worth noting the Demi is a self-cleaning system, which means it'll fit into your kitchen sleekly without bringing high-maintenance upkeep into the room. Of late, coffee makers have been embracing color – and I'm a huge fan. Take De'Longhi's launch of the Dedica Duo thundering in with four different gelato-inspired shades, or the Technivorm Moccamaster bringing an Ocean offering to its already colorful range. Then, there's the Fellow Aiden launching in Matte White and then the Keurig K-Mini Mate taught me that Glamping Green and Red Rocks are two colorways I didn't know I needed. So, I'm not surprised to see that Terra Kaffe is following suit. While the TK-02 came in stunning White and Black, the Demi launches with an even wider range of color tones. Four, in fact, and all with wonderfully sleek names. For Demi, you can pick between Cloud, Slate, Forest or Sand. And the only real issue I have with this is that I can't pick which one's my favorite. If you dangled a mug of hot espresso over my hand and made me though, I'd go with Forest. There's something about a muted green that apparently makes me very thirsty. I'll reserve my final judgement for when we get our hands on the Demi for a full review. And if it's anything like its predecessor, I can't wait.
